Axonal Transport Dysfunction Validation in Parkinson's Disease

PRIMARY OUTCOME

Quantification of axonal transport dysfunction severity using DTI-derived metrics and CSF neurofilament levels, demonstrating significant correlation with disease progression rates over 24-month follow-up period.

EXPECTED OUTCOMES

**Primary Outcome Measures: Quantitative Axonal Transport Dysfunction Characterization** Phase 1 (Baseline, Month 0): Establishment of axonal transport impairment signatures across patient populations. DTI-derived metrics (Fractional Anisotropy, Mean Diffusivity, Axial Diffusivity) will demonstrate significant reductions in substantia nigra pars compacta (SNpc) of early-stage PD patients (mean FA reduction 12-18% versus controls, p<0.01) and mid-stage patients (24-32% reduction). CSF phosphorylated neurofilament heavy chain (pNfH) levels will show 2.5-3.5 fold elevation in PD cohorts (early-stage: 8-15 pg/mL; mid-stage: 15-28 pg/mL) versus healthy controls (2-4 pg/mL). Plasma biomarkers including pNfH, total tau, and phosphorylated tau (p-tau181) will demonstrate significant elevation with Cohen's d effect sizes >0.8 across groups. **Phase 2 (Longitudinal Characterization, Months 6-24): Disease Progression Correlation Analysis** Annualized changes in DTI metrics will correlate strongly with UPDRS motor score progression (r>0.65, p<0.001). CSF neurofilament biomarkers will predict motor decline velocity with area-under-curve (AUC) >0.78 on receiver operating characteristic analysis. Proteomics profiling via LC-MS/MS will identify 15-25 significantly dysregulated axonal transport proteins, including kinesin motors (KIF5A, KIF5B, KIF1A), dynein regulators (DYNC1H1), and adaptors (TRAK1, TRAK2), with >1.5-fold expression changes and adjusted p-values <0.01. RNA-sequencing of PBMCs will reveal coordinated dysregulation of GAP43, HNRNPA2B1, and MAP6 transcripts with normalized expression changes >|0.8| log2-fold relative to controls. **Phase 3 (Mechanistic Integration, Month 24): Multi-Modal Biomarker Convergence** Integrated multi-omics analysis will establish mechanistic pathways linking imaging, proteomic, transcriptomic, and biofluid biomarkers. Functional connectivity analysis from rs-fMRI will show 25-40% reduction in nigrostriatal pathway coherence in mid-stage patients. Voxel-wise TBSS analysis will identify 2,000-4,000 voxels with significant FA reductions (p<0.05 family-wise error corrected). DAT-SPECT specific binding ratios will decline at annualized rates of 8-12% in early-stage and 12-18% in mid-stage patients, demonstrating parallel dopaminergic neurodegeneration. Cognitive decline (Montreal Cognitive Assessment score changes) will show moderate correlation with axonal transport markers (r>0.55, p<0.01), identifying potential cognitive consequences of impaired neuronal transport mechanisms.

SUCCESS CRITERIA

**Primary Success Criterion 1: Statistical Significance and Effect Size Thresholds** Achievement requires demonstration of statistically significant differences (p<0.05, Bonferroni-corrected for multiple comparisons) between PD patients and healthy controls across primary outcome measures. Specifically: (1) DTI metrics in SNpc must show Cohen's d effect sizes ≥1.2 for FA and AD, and ≥0.9 for MD; (2) CSF pNfH levels must differ with Cohen's d ≥1.5; (3) plasma biomarker panels must achieve Cohen's d ≥0.9 across ≥70% of measured analytes; (4) proteomics data must identify ≥20 significantly dysregulated axonal transport proteins (adjusted p<0.01, fold-change ≥1.5); (5) RNA-sequencing must show coordinated dysregulation of GAP43, HNRNPA2B1, and MAP6 (adjusted p<0.01). Additionally, receiver operating characteristic analysis must achieve area-under-curve values ≥0.75 for discriminating PD patients from controls using biomarker combinations. **Primary Success Criterion 2: Mechanistic Linkage Validation** Demonstration of clear, mechanistically-plausible connections between axonal transport dysfunction and dopaminergic neurodegeneration requires: (1) significant longitudinal correlations (Pearson r>0.60, p<0.001) between baseline axonal transport impairment (composite scores integrating DTI, biofluid, and proteomic measures) and 24-month disease progression rates assessed via annualized UPDRS motor decline and DAT-SPECT binding ratio changes; (2) mediation analysis showing that axonal transport dysfunction variables explain ≥45% of variance in dopaminergic decline; (3) pathway analysis demonstrating convergence of dysregulated proteins onto molecular nodes (TRAK1/KIF5, mitochondrial dynamics, RNA granule assembly) with biological relevance to mitochondrial transport and neuronal survival; (4) identification of at least 3 distinct molecular subclusters (motor protein dysfunction, mitochondrial dynamics impairment, RNA transport defects) each showing significant independent association with phenotypic progression (p<0.01); (5) functional validation showing that in vitro rescue of identified dysregulated pathways (via overexpression of TRAK1-KIF5 fusion constructs or MAP6 enhancement) restores axonal transport metrics in patient-derived neurons. **Primary Success Criterion 3: Reproducibility and Generalizability** Findings must demonstrate reproducibility across independent validation cohorts (target: replication in ≥2 independent PD patient populations from different medical centers, minimum n=50 per cohort). Success requires: (1) consistent direction and magnitude of biomarker changes across cohorts (≥80% agreement in effect size rankings); (2) validation of biomarker-progression correlations achieving similar r and p-value thresholds in replication cohorts (r>0.55, p<0.01); (3) external validation of machine learning classifiers integrating imaging and biofluid biomarkers achieving ≥78% sensitivity and ≥72% specificity for PD classification in held-out test sets; (4) demonstration that top-ranked dysregulated proteins and transcripts show conserved directional changes across independent patient populations; (5) publication of preregistered analysis protocols prior to unblinded data analysis with ≥90% adherence to specified analytic approaches. Robust statistical approaches including cross-validation, bootstrapped confidence intervals (95% CI), and sensitivity analyses accounting for age, sex, disease duration, and medication exposure must substantiate generalizability of findings across PD patient heterogeneity.

PROTOCOL

**Study Design and Participant Recruitment** This prospective longitudinal clinical validation study enrolls 200 Parkinson's Disease patients (100 early-stage: Hoehn-Yahr stages 1-2; 100 mid-stage: stages 2.5-3) and 100 age-matched healthy controls (HC) stratified by age decade (50-60, 60-70, 70-80 years). PD diagnosis follows Movement Disorder Society criteria with confirmed dopaminergic deficit on DAT-SPECT imaging. Exclusion criteria include secondary parkinsonism, prior neurosurgical intervention, MRI contraindications, or significant cerebrovascular disease. Participants undergo baseline assessments including Unified Parkinson's Disease Rating Scale (UPDRS), Montreal Cognitive Assessment, and comprehensive medication inventories with washout protocols for dopaminergic agents (12-hour minimum) before testing. **Advanced Neuroimaging Protocol** High-field 3T MRI with echo-planar diffusion imaging acquires 64-direction diffusion-weighted sequences (b=1000, 2000, 3000 s/mm²) with 2mm³ isotropic voxels. Fractional Anisotropy (FA), Mean Diffusivity (MD), and Axial Diffusivity (AD) metrics undergo region-of-interest analysis in substantia nigra pars compacta (SNpc), striatal subdivisions (dorsolateral putamen, ventromedial putamen, caudate), and corticospinal tracts as control regions. Tract-Based Spatial Statistics (TBSS) enables voxel-wise group comparisons. Resting-state functional MRI (rs-fMRI, TR=2.2s, 10-minute acquisition) quantifies functional connectivity within nigrostriatal circuits using seed-based analysis from manually-traced SNpc regions of interest. **Biofluid Analysis and Molecular Characterization** Cerebrospinal fluid (CSF) collection via lumbar puncture (L3-L4 or L4-L5) employs standardized protocols with immediate centrifugation at 1,500g for 10 minutes and aliquoting into polypropylene tubes for −80°C storage. Plasma samples from peripheral venipuncture undergo identical processing. Ultrasensitive single-molecule array (Simoa) technology quantifies phosphorylated neurofilament heavy chain (pNfH) and total tau (t-tau) with lower limits of detection <0.1 pg/mL. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) targets 247 proteomic markers including kinesin motor proteins (KIF5A, KIF5B, KIF1A), dynein components (DYNC1H1), adaptor proteins (TRAK1, TRAK2), and mitochondrial dynamics regulators (OPA1, DRP1, PINK1). Parallel reaction monitoring (PRM) ensures quantitative accuracy with heavy isotope-labeled internal standards. RNA-sequencing from peripheral blood mononuclear cells (PBMCs) characterizes transcriptomic signatures of axonal transport-related genes (GAP43, HNRNPA2B1, MAP6, plus 48 related transcripts) using stranded RNA-seq with ≥50 million paired-end reads per sample. **Longitudinal Follow-up and Endpoint Assessment** Participants return for repeat assessments at 6, 12, and 24-month intervals with identical neuroimaging, biofluid sampling, and clinical scoring protocols. Disease progression quantification employs annualized change in UPDRS motor scores and DAT-SPECT specific binding ratios. Cognitive decline assessment uses serial Montreal Cognitive Assessment scores. All samples are analyzed in batch format at study conclusion to minimize inter-assay variability.

LINKED HYPOTHESES

Scoring Dimensions

Prerequisite Graph (6 upstream, 4 downstream)

Missions

Prediction Markets (1 direct, 0 via hypothesis — 1 total)

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Axonal Transport Dysfunction Validation in Parkinson's Disease](http://scidex.ai/artifact/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons)

Direct URL

http://scidex.ai/artifact/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons

Preview